NALLELI GARRIDO: Open Payments
NPI 1164001038 · SANTA ANA, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,221 in 43 payments from 11 companies in 2025. Trend: 2023 $129 · 2024 $2,677 · 2025 $1,221
Food & beverage: $1,221
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 12 | $408 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 6 | $196 |
| ABBVIE INC. | 9 | $166 |
| Axsome Therapeutics, Inc. | 3 | $142 |
| Otsuka America Pharmaceutical, Inc. | 4 | $103 |
| Janssen Pharmaceuticals, Inc | 2 | $56 |
| Lundbeck LLC | 2 | $46 |
| Tris Pharma Inc | 2 | $38 |
| Neurocrine BioSciences, Inc. | 1 | $38 |
| Alkermes, Inc. | 1 | $15 |
Products named: FANAPT, CAPLYTA, VRAYLAR, Auvelity, REXULTI, ABILIFY ASIMTUFII, Dyanavel XR, INGREZZA.
Industry payments across CA — which companies pay providers there.
